Amedisys Inc (NASDAQ:AMED) Rating Reiterated by SunTrust Banks, Inc.

SunTrust Banks, Inc. restated their buy rating on shares of Amedisys Inc (NASDAQ:AMED) in a report issued on Monday, October 9th. They currently have a $60.00 price target on the health services provider’s stock.

A number of other equities analysts have also weighed in on the company. Robert W. Baird reiterated a hold rating and set a $50.00 price objective on shares of Amedisys in a research note on Wednesday, October 4th. Oppenheimer Holdings, Inc. restated a buy rating and set a $60.00 target price on shares of Amedisys in a research report on Friday, September 15th. Bank of America Corporation initiated coverage on Amedisys in a research report on Monday, August 21st. They set a neutral rating and a $55.00 target price on the stock. BidaskClub upgraded Amedisys from a sell rating to a hold rating in a research report on Friday, August 11th. Finally, Mizuho cut Amedisys from a buy rating to a neutral rating and set a $50.00 target price on the stock. in a research report on Wednesday, July 26th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $56.20.

Shares of Amedisys (NASDAQ AMED) opened at 50.27 on Monday. Amedisys has a 12-month low of $34.58 and a 12-month high of $65.91. The company has a market capitalization of $1.70 billion, a PE ratio of 42.97 and a beta of 0.87. The stock’s 50 day moving average price is $51.65 and its 200 day moving average price is $55.05.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The business had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $0.42 EPS. On average, equities research analysts forecast that Amedisys will post $2.21 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Amedisys Inc (NASDAQ:AMED) Rating Reiterated by SunTrust Banks, Inc.” was originally posted by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://baseballnewssource.com/markets/amedisys-inc-amed-stock-rating-reaffirmed-by-suntrust-banks-inc/1704394.html.

In other Amedisys news, Director Bruce D. Perkins bought 2,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The shares were acquired at an average cost of $46.60 per share, with a total value of $93,200.00. Following the purchase, the director now directly owns 15,825 shares of the company’s stock, valued at approximately $737,445. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now directly owns 10,488 shares in the company, valued at $524,400. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Riverhead Capital Management LLC raised its position in shares of Amedisys by 75.5% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after buying an additional 831 shares during the period. Federated Investors Inc. PA raised its position in shares of Amedisys by 2.3% during the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after buying an additional 44 shares during the period. Ameritas Investment Partners Inc. purchased a new stake in shares of Amedisys during the 1st quarter valued at approximately $123,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Amedisys during the 3rd quarter valued at approximately $205,000. Finally, CIBC Asset Management Inc purchased a new stake in shares of Amedisys during the 2nd quarter valued at approximately $230,000. 96.55% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.